Status:
UNKNOWN
Topical Steroids and Cyclosporin-A for COVID-19 Keratoconjunctivitis
Lead Sponsor:
Ameera Gamal Abdelhameed
Collaborating Sponsors:
Ministry of Health, Kuwait
Conditions:
Keratonjunctivitis
Eligibility:
All Genders
Phase:
NA
Brief Summary
To explore the feasibility of combined topical corticosteroid and topical cyclosporine-A in COVID-19 patients with acute keratoconjunctivitis.
Detailed Description
COVID-19 patients presenting with acute keratoconjunctivitis will be treated with Topical 1% prednisolone acetate fourTimes daily for 7 days as initial treatment, non-preserved artificial tears four t...
Eligibility Criteria
Inclusion
- COVID-19 Patients with keratoconjunctivitis
Exclusion
- associated ocular pathology or disease
- other causes of keratoconjunctivitis for example allergic or herpetic
Key Trial Info
Start Date :
June 30 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2020
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT04451239
Start Date
June 30 2020
End Date
July 1 2020
Last Update
June 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Farawanyia hospital
Kuwait City, Farawanyia, Kuwait